Response of differentiated but not anaplastic teratoma to interferon.

A Phase 2 trial was conducted using intramuscular lymphoblastoid interferon (IFN, Wellcome Research Laboratories), 4 MU per day, in 10 patients with chemotherapy-resistant teratomas. There was stabilisation of disease in 2 patients both of whom were in retrospect considered to have had differentiate...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustin, G. J., Kaye, S. B., Williams, C. J., Newlands, E. S., Bagshawe, K. D., Toy, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1984
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976992/
https://www.ncbi.nlm.nih.gov/pubmed/6498061
_version_ 1782135168205586432
author Rustin, G. J.
Kaye, S. B.
Williams, C. J.
Newlands, E. S.
Bagshawe, K. D.
Toy, J. L.
author_facet Rustin, G. J.
Kaye, S. B.
Williams, C. J.
Newlands, E. S.
Bagshawe, K. D.
Toy, J. L.
author_sort Rustin, G. J.
collection PubMed
description A Phase 2 trial was conducted using intramuscular lymphoblastoid interferon (IFN, Wellcome Research Laboratories), 4 MU per day, in 10 patients with chemotherapy-resistant teratomas. There was stabilisation of disease in 2 patients both of whom were in retrospect considered to have had differentiated teratoma at the time of IFN administration. There was progression of presumed active anaplastic germ cell tumour in 8 patients. One of these patients, a 15-year-old boy with biopsy proven differentiated teratoma has received 2 courses of lymphoblastoid IFN and 1 course of recombinant leukocyte A IFN (Roche Products Ltd.) lasting 5 1/2, 8 and 8+ months respectively. He has had a mixed response in his differentiated tumour which on each occasion has been maintained for the duration that he received IFN. Rising HCG levels during his second course of interferon required additional cytotoxic chemotherapy. Lymphoblastoid IFN does not appear to be active against anaplastic germ cell tumours but both lymphoblastoid and recombinant leukocyte A IFN may be useful in the treatment of unresectable differentiated teratoma. IMAGES:
format Text
id pubmed-1976992
institution National Center for Biotechnology Information
language English
publishDate 1984
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19769922009-09-10 Response of differentiated but not anaplastic teratoma to interferon. Rustin, G. J. Kaye, S. B. Williams, C. J. Newlands, E. S. Bagshawe, K. D. Toy, J. L. Br J Cancer Research Article A Phase 2 trial was conducted using intramuscular lymphoblastoid interferon (IFN, Wellcome Research Laboratories), 4 MU per day, in 10 patients with chemotherapy-resistant teratomas. There was stabilisation of disease in 2 patients both of whom were in retrospect considered to have had differentiated teratoma at the time of IFN administration. There was progression of presumed active anaplastic germ cell tumour in 8 patients. One of these patients, a 15-year-old boy with biopsy proven differentiated teratoma has received 2 courses of lymphoblastoid IFN and 1 course of recombinant leukocyte A IFN (Roche Products Ltd.) lasting 5 1/2, 8 and 8+ months respectively. He has had a mixed response in his differentiated tumour which on each occasion has been maintained for the duration that he received IFN. Rising HCG levels during his second course of interferon required additional cytotoxic chemotherapy. Lymphoblastoid IFN does not appear to be active against anaplastic germ cell tumours but both lymphoblastoid and recombinant leukocyte A IFN may be useful in the treatment of unresectable differentiated teratoma. IMAGES: Nature Publishing Group 1984-11 /pmc/articles/PMC1976992/ /pubmed/6498061 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Rustin, G. J.
Kaye, S. B.
Williams, C. J.
Newlands, E. S.
Bagshawe, K. D.
Toy, J. L.
Response of differentiated but not anaplastic teratoma to interferon.
title Response of differentiated but not anaplastic teratoma to interferon.
title_full Response of differentiated but not anaplastic teratoma to interferon.
title_fullStr Response of differentiated but not anaplastic teratoma to interferon.
title_full_unstemmed Response of differentiated but not anaplastic teratoma to interferon.
title_short Response of differentiated but not anaplastic teratoma to interferon.
title_sort response of differentiated but not anaplastic teratoma to interferon.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976992/
https://www.ncbi.nlm.nih.gov/pubmed/6498061
work_keys_str_mv AT rustingj responseofdifferentiatedbutnotanaplasticteratomatointerferon
AT kayesb responseofdifferentiatedbutnotanaplasticteratomatointerferon
AT williamscj responseofdifferentiatedbutnotanaplasticteratomatointerferon
AT newlandses responseofdifferentiatedbutnotanaplasticteratomatointerferon
AT bagshawekd responseofdifferentiatedbutnotanaplasticteratomatointerferon
AT toyjl responseofdifferentiatedbutnotanaplasticteratomatointerferon

Ejemplares similares